https://orcid.org/0000-0002-2088-0899
Key Points
Among CLL/SLL patients treated with 1L ibrutinib, similar rwOS was observed for those with or without high-risk cytogenetic features
Study results further support the use of 1L ibrutinib in patients with CLL/SLL, regardless of cytogenetic risk
In patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), high-risk cytogenetic features such as del(17p), del(11q), and unmutated immunoglobulin variable heavy chain (IGHV) may be associated with unfavorable outcomes. In this large retrospective cohort study, data from a nationwide electronic health record-derived deidentified database were analyzed to assess real-world overall survival (rwOS) among patients treated with first-line (IL) ibrutinib with and without high-risk cytogenetic features (i.e., del(17p), del(11q), unmutated IGHV). Inverse probability of treatment weighting was used to account for differences in patient characteristics between cohorts. Of the 1,242 patients included, 969 and 273 had high- and non-high-risk CLL/SLL, with a mean age of 70.0 and 70.8 years, and a median follow up of 32 and 31 months, respectively. Within the high-risk cohort, 32.9%, 36.7%, and 58.7% had the presence of del(17p), del(11q), and unmutated IGHV, respectively. Median rwOS was not reached for either cohort; the hazard ratio (HR; 95% confidence interval [CI]) comparing rwOS between the two cohorts was 1.09 (0.79, 1.51). In a sensitivity analysis where del(11q) was not part of the high-risk definition, similar results were found, with a HR (95% CI) of 1.19 (0.86, 1.64) and median rwOS not reached for either cohort. Similarly, among the subgroup of patients with Medicare coverage, the HR (95% CI) was 0.98 (0.63, 1.53), and median rwOS was not reached. In this real-world study using a large community healthcare dataset, there was no difference in rwOS between patients treated with 1L ibrutinib with and without high-risk cytogenetic features.
